Herbs (Global Traditional) · African
Umuzi (Sutherlandia frutescens) (Sutherlandia frutescens)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Sutherlandia frutescens contains flavonoids and triterpene saponins that demonstrate antioxidant activity through DPPH radical scavenging mechanisms. The plant shows preliminary anti-cancer potential by disrupting cellular ATP production and increasing adenylate kinase release in laboratory studies.
Umuzi (Sutherlandia frutescens) is a shrub native to Southern Africa, particularly South Africa, belonging to the Fabaceae family. The plant's leaves, stems, and seeds are harvested and processed using methanol extraction followed by n-butanol fractionation and chromatographic purification to isolate bioactive glycosides. The plant contains triterpene glycosides, flavonoids, amino acids, and other compounds classified as saponins and polyphenols.
No human clinical trials, randomized controlled trials, or meta-analyses for Sutherlandia frutescens were identified in the research dossier. All available evidence comes from in vitro laboratory studies examining antioxidant capacity and anticancer effects in cell cultures. The absence of clinical trial data or PubMed PMIDs indicates a significant research gap for this traditional remedy.
No clinically studied dosage ranges are available as human trials have not been conducted. Phytochemical studies have standardized extracts to contain sutherlandioside B at 10.1 µg/mg in aqueous preparations. Traditional preparations include infusions, decoctions, or powders from leaves and stems. Consult a healthcare provider before starting any new supplement.
Sutherlandia frutescens (Cancer Bush/Umuzi) is primarily used as a medicinal herb rather than a food source, so nutritional data reflects dried leaf/aerial parts used in preparations. Bioactive compounds dominate the profile: L-canavanine (a non-protein amino acid antimetabolite) at approximately 1-7 mg/g dry weight in leaves — this is the primary pharmacologically active constituent but also potentially toxic at high doses; GABA (gamma-aminobutyric acid) at approximately 1-6 mg/g dry weight, contributing to possible anxiolytic effects; pinitol (D-pinitol, a cyclitol sugar) at approximately 5-15 mg/g dry weight, associated with insulin-mimetic and anti-diabetic activity and considered a key active compound. Flavonoids including kaempferol, quercetin, and hyperoside are present at combined concentrations of approximately 10-30 mg/g dry weight (as aglycone equivalents), contributing to antioxidant activity. Triterpenoid saponins (sutherlandiosides A-D and cycloartane-type glycosides) are present and contribute to immunomodulatory and anti-cancer properties. Protein content of dried leaf material is approximately 15-20% by dry weight, though bioavailability is limited due to L-canavanine competition with L-arginine in protein synthesis. Crude fiber approximately 20-25% dry weight. Mineral content includes iron (~150-200 mg/kg dry weight), zinc (~20-30 mg/kg), and potassium (~8-12 g/kg). Vitamin C has been reported in fresh material (~50-100 mg/100g fresh weight). Bioavailability note: L-canavanine may interfere with arginine-dependent metabolic pathways, and saponins may reduce absorption of co-administered nutrients. Aqueous extracts (traditional tea preparation) show good solubility of GABA and pinitol but variable extraction of saponins.
Sutherlandia frutescens exerts antioxidant effects through flavonoid compounds that scavenge DPPH radicals and enhance ferric reducing antioxidant power (FRAP). The plant's triterpene saponins appear to disrupt mitochondrial function in cancer cells by depleting ATP content and triggering adenylate kinase release, indicating cellular membrane damage. Traditional therapeutic effects may involve immune system modulation, though specific molecular pathways remain under investigation.
Current evidence for Sutherlandia frutescens consists primarily of in vitro laboratory studies demonstrating antioxidant activity through DPPH and FRAP assays. Anti-cancer research is limited to cell line studies showing reduced ATP levels and increased adenylate kinase release, indicating cytotoxic effects. No large-scale human clinical trials have been conducted to validate therapeutic claims. Traditional use for HIV/AIDS symptom management lacks controlled clinical evidence, though the plant remains widely used in African traditional medicine systems.
Sutherlandia frutescens safety profile in humans remains poorly documented due to limited clinical research. The plant may interact with antiretroviral medications and immunosuppressive drugs given its traditional use in HIV/AIDS management. Pregnancy and breastfeeding safety have not been established through controlled studies. Potential side effects and appropriate dosing ranges require further investigation through human trials.
